Yale Cancer Center Researchers Report Results of Afatinib plus Cetuximab for Treatment of EGFR-Mutant NSCLC
Results of a new study led by Yale Cancer Center researchers shows the addition of cetuximab to afatinib versus afatinib alone did not improve outcomes in previously-untreated epidermal growth factor receptor mutant, non-small cell lung cancer.
Atezolizumab Appears Effective for Patients with NSCLC with High PD-L1 Expression
Atezolizumab (Tecentriq) treatment resulted in significantly longer overall survival (OS) compared with platinum-based chemotherapy among patients with non-small cell lung cancer (NSCLC) with high PD-L1 expression, regardless of histologic type, according to results from a phase 3 trial published in the New England Journal of Medicine.Source: Cancer Network
Yale Cancer Center Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
Yale Pathology Professor Receives NIH Award for Breakthrough Cancer Research
The award — granted to just 5% of NIH-funded investigators —ensures that Kurt Schalper’s research will be funded for the next seven years. It supports his groundbreaking work identifying novel pathways for cancer immunotherapy which can be used to optimally select and treat patients with non-small cell lung cancer.Source: YaleNews
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042
Prof Roy Herbst speaks to ecancer at ESMO 2019 in Barcelona about the association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials.Source: ecancer.org
Cancer Cure 2019: Immunotherapy Drug Under Research Shows Promising Result for Lung Cancer Patients
Finding the complete cure for cancer remains a Herculean task for many researchers around the world. And while that has yet to be achieved, other groups of scientists are working on the next best thing — developing immunotherapy drugs to increase the survivability rate among cancer patients.Source: EconoTimes
Yale Cancer Center Scientists Receive Grant to Advance Lung Cancer Research
Katerina Politi, PhD and Don Nguyen, PhD, members of the Signal Transduction Research Program at Yale Cancer Center (YCC), have received a 5-year, nearly $4 million National Cancer Institute (NCI) grant to support Lung Cancer research.
New Tool Helps Find Genetic Culprits in Cancer’s Spread
The ability of cancer to establish itself in distant parts of the body — called metastasis — causes 90% of deaths from solid tumors. Metastasis is the result of complex genetic interactions that have proven difficult for scientists to study. Now Yale researchers have devised a way to identify some of the most dangerous of those interactions.
Zai Lab Announces the Appointment of Immuno-Oncology Pioneer, Lieping Chen, M.D., Ph.D., to its Scientific Advisory Board
Zai Lab Limited, a China and US-based innovative commercial stage biopharmaceutical company announced the appointment of Lieping Chen, MD, PhD, to its Scientific Advisory Board.Source: AP News